Live tape
Top 8, mentions 7d11,838NVDA5,050 mentions▲ +0.08GOOGL1,520 mentions▲ +0.02META1,235 mentions▲ +0.05NKE1,170 mentions+0.01MRVL842 mentions▲ +0.08SNDK720 mentions▲ +0.07MSFT681 mentions▲ +0.06QQQ620 mentions▲ +0.07

Equity · Healthcare

CVS

CVS Health Corporation · NYSE

$99.11 −5.06% 1D Finazon · prior-day close · Aug 5, 2026
Price · Chart
Our own end-of-day closes 45 sessions
$120 $80 2 Jun 5 Aug

The line runs $89.51 on 2 June through $99.11 on 5 August, on a scale from $80 to $120. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of CVS over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 45 sessions over that window: $89.51 on 2 June 2026 through $99.11 on 5 August 2026.

Market cap $126.8B
P/E (TTM) 43.5
52-week range $60.01 – $110.58
Avg volume 1.7M

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 31, 2026

CVS insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 26 Jun 2026
Open-market buys 0
Open-market sells 0
Non-trade filings 1

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
26 Jun 2026 Clark James David SVP, Cont & Chief Acct Officer Tax withheld 454 $41K

CVS reported financials

SEC EDGAR XBRL

CVS reported revenue of $402.1B for the fiscal year ended 31 Dec 2025. Net income over the same period was $1.8B.

Figure Reported Period
Revenue $402.1B 31 Dec 2025 fiscal year
Net income $1.8B 31 Dec 2025 fiscal year
Diluted EPS $1.39 31 Dec 2025 fiscal year
Total assets $253.8B 30 Jun 2026 at period end
Total equity $79.7B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

CVS earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $2.31 $106.10B
31 Mar 2026 Q1 2026 $2.30 $100.43B
31 Dec 2025 FY 2025 $1.39 $402.07B
30 Sep 2025 Q3 2025 $-3.13 $102.87B
30 Jun 2025 Q2 2025 $0.80 $98.92B
31 Mar 2025 Q1 2025 $1.41 $94.59B
31 Dec 2024 FY 2024 $3.66 $372.81B
30 Sep 2024 Q3 2024 $0.07 $95.43B

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

CVS institutional holders

SEC Form 13F

15 of the 45 institutional funds we track reported a CVS position for the quarter ended 30 Jun 2026 — a combined $2.4B; the latest of those filings landed 14 Aug 2026.

Fund Action Shares Value
Glenview Capital Management Trimmed −41.1% shares 4,824,799 $499.1M
Citadel Advisors Held (±25%) −11.3% shares 4,812,530 $497.9M
Viking Global Investors New position 3,663,361 $379.0M
AQR Capital Management Held (±25%) +1.0% shares 2,411,937 $248.9M
Millennium Management Added +1,013.6% shares 2,164,833 $224.0M
Point72 Asset Management New position 1,961,032 $202.9M
D. E. Shaw & Co. Held (±25%) −14.6% shares 1,382,037 $143.0M
Renaissance Technologies Added +67.6% shares 441,016 $45.6M
Bridgewater Associates Trimmed −28.7% shares 440,972 $45.6M
Tudor Investment Corp Trimmed −45.7% shares 370,000 $38.3M

Showing the 10 largest of 15 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings

CVS fails-to-deliver

SEC CNS data

On 22 Jul 2026, 12 shares of CVS failed to deliver (about $1K) — the latest of at least 4 consecutive trading days with recorded fails. The run reaches the start of the window we read, so it may have begun earlier.

Settlement date Shares failed Notional % of shares out
22 Jul 2026 12 $1K <0.001%
21 Jul 2026 12 $1K <0.001%
20 Jul 2026 17 $2K <0.001%
17 Jul 2026 12 $1K <0.001%

Source: SEC fails-to-deliver (CNS) data

Congressional trades in CVS

STOCK Act disclosures

The most recent congressional trade disclosed in CVS is a sale by Dwight Evans (house, PA), dated 21 Nov 2025.

Date Member Type Amount
21 Nov 2025 filed 15 May 2026 Dwight Evans house · Democrat–PA Sale $1K–$15K

Source: U.S. House of Representatives financial disclosures